R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life
- PMID: 34112729
- DOI: 10.1183/13993003.00917-2021
R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life
Abstract
Rationale: Patients with idiopathic pulmonary fibrosis (IPF) experience impaired health-related quality of life (HRQoL). Several tools have been developed to objectively assess HRQoL in this patient population, but none are in use in routine clinical practice.
Objectives: To develop a rapid, specific tool that can be used for patients with IPF during routine clinic visits.
Methods: A novel and simple five-item numerical rating scale was developed and compared with two other previously validated tools. 100 consecutive patients with IPF managed at a centre for interstitial lung disease were recruited to complete the Raghu scale for pulmonary fibrosis (R-Scale-PF), King's Brief Interstitial Lung Disease questionnaire (K-BILD), and the EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L) in addition to pulmonary function and 6-min walk tests.
Measurements and main results: All 100 patients successfully completed the three HRQoL tools with 53 completing them again at follow-up visits. Internal consistency was high (Cronbach's α 0.825) with minimal floor/ceiling effect. Concurrent validity of the R-Scale-PF was moderate to high compared with the K-BILD (r=-0.713) and the EQ-5D-5L (r=-0.665). Concurrent validity was moderate with physiologic measures (forced vital capacity, r=-0.307, 6-min walking distance, r=-0.383). The R-Scale-PF demonstrated good known-groups validity when comparing scores across stages of disease severity.
Conclusions: The R-Scale-PF correlates well with the K-BILD and EQ-5D-5L. It is hoped that this novel simple numerical rating scale tool, subject to validation in patients from other centres, will provide an opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.
Trial registration: ClinicalTrials.gov NCT04148157.
Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: C. Scallan has nothing to disclose. Conflict of interest: L. Strand has nothing to disclose. Conflict of interest: J. Hayes has nothing to disclose. Conflict of interest: S. Kadura has nothing to disclose. Conflict of interest: B. Collins reports personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work. Conflict of interest: L. Ho has nothing to disclose. Conflict of interest: C. Spada has nothing to disclose. Conflict of interest: W. Canestaro has nothing to disclose. Conflict of interest: M. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation and Canadian Institute for Health Research, other (site PI in industry-sponsored clinical trials) from Roche, grants, personal fees for advisory board work and other (site PI in industry-sponsored clinical trials) from Boehringer Ingelheim, grants and personal fees for advisory board work from Roche, Liminal and Pieris, other (chief editor allowance) from European Respiratory Journal, personal fees for advisory board work from Third Pole, MitoImmune, Abbvie, DevPro Biopharma, Horizon, Algernon and CSL Behring, outside the submitted work. Conflict of interest: G. Raghu has nothing to disclose.
Comment in
-
PROMising developments in IPF patient-reported outcome measures.Eur Respir J. 2022 Jan 13;59(1):2102312. doi: 10.1183/13993003.02312-2021. Print 2022 Jan. Eur Respir J. 2022. PMID: 35027375 No abstract available.
Similar articles
-
Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.BMC Pulm Med. 2019 Dec 19;19(1):255. doi: 10.1186/s12890-019-1018-0. BMC Pulm Med. 2019. PMID: 31856786 Free PMC article.
-
Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26. Chron Respir Dis. 2017. PMID: 28019103 Free PMC article.
-
Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.Respir Res. 2018 May 25;19(1):101. doi: 10.1186/s12931-018-0808-x. Respir Res. 2018. PMID: 29801506 Free PMC article.
-
Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Eur Respir Rev. 2020 Nov 5;29(158):200154. doi: 10.1183/16000617.0154-2020. Print 2020 Dec 31. Eur Respir Rev. 2020. PMID: 33153990 Free PMC article.
-
Integrating the assessment of quality of life in care and research in pulmonary fibrosis.Curr Opin Pulm Med. 2024 Sep 1;30(5):508-515. doi: 10.1097/MCP.0000000000001095. Epub 2024 Jul 1. Curr Opin Pulm Med. 2024. PMID: 38946547 Review.
Cited by
-
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.Pulm Circ. 2022 Oct 1;12(4):e12178. doi: 10.1002/pul2.12178. eCollection 2022 Oct. Pulm Circ. 2022. PMID: 36578976 Free PMC article. Review.
-
Holistic management of patients with progressive pulmonary fibrosis.Breathe (Sheff). 2023 Sep;19(3):230101. doi: 10.1183/20734735.0101-2023. Epub 2023 Sep 12. Breathe (Sheff). 2023. PMID: 37719243 Free PMC article. Review.
-
Assessing health-related quality of life in patients with interstitial lung diseases.BMC Pulm Med. 2024 Sep 13;24(1):452. doi: 10.1186/s12890-024-03262-9. BMC Pulm Med. 2024. PMID: 39272068 Free PMC article.
-
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO. Am J Respir Crit Care Med. 2024. PMID: 38174955 Free PMC article.
-
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8. BMC Pulm Med. 2022. PMID: 36514019 Free PMC article.
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical